{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:20:07Z","timestamp":1793035207560,"version":"4.5.0"},"publisher-location":"Cham","reference-count":33,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030430313","type":"print"},{"value":"9783030430320","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-43032-0_15","type":"book-chapter","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T08:02:53Z","timestamp":1590998573000},"page":"181-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":190,"title":["Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention"],"prefix":"10.1007","author":[{"given":"Anchit","family":"Bhagat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie S.","family":"Kleinerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"issue":"22","key":"15_CR1","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401.Anthracycline","volume":"26","author":"L Gianni","year":"2011","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB (2011) Anthracycline cardiotoxicity: from bench to bedside. NIH Public Access 26(22):3777\u20133784. https:\/\/doi.org\/10.1200\/JCO.2007.14.9401.Anthracycline","journal-title":"NIH Public Access"},{"issue":"1","key":"15_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"15_CR3","first-page":"84","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84\u201389","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"15_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","volume":"82","author":"SH Chen","year":"2013","unstructured":"Chen SH, Chan N-L, Hsieh T (2013) New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem 82(1):139\u2013170. https:\/\/doi.org\/10.1146\/annurev-biochem-061809-100002","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"15_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","volume":"70","author":"JJ Champoux","year":"2001","unstructured":"Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70(1):369\u2013413","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"15_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2013.201","volume":"95","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ETH (2014) Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95(1):45\u201352. https:\/\/doi.org\/10.1038\/clpt.2013.201","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"15_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.5483\/bmbrep.2006.39.6.759","volume":"39","author":"B Liu","year":"2006","unstructured":"Liu B, Li H, Qu H, Sun B (2006) Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. BMB Rep 39(6):759\u2013765. https:\/\/doi.org\/10.5483\/bmbrep.2006.39.6.759","journal-title":"BMB Rep"},{"issue":"8","key":"15_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0973-7847.70902","volume":"4","author":"V Lobo","year":"2010","unstructured":"Lobo V, Patil A, Phatak A, Chandra N (2010) Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev 4(8):118. https:\/\/doi.org\/10.4103\/0973-7847.70902","journal-title":"Pharmacogn Rev"},{"issue":"2","key":"15_CR9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.59566\/IJBS.2008.4089","volume":"4","author":"LA Pham-Huy","year":"2008","unstructured":"Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci 4(2):89\u201396","journal-title":"Int J Biomed Sci"},{"issue":"11","key":"15_CR10","doi-asserted-by":"publisher","first-page":"3143S","DOI":"10.1093\/jn\/134.11.3143S","volume":"134","author":"HE Seifried","year":"2004","unstructured":"Seifried HE, Anderson DE, Sorkin BC, Costello RB (2004) Free radicals: the pros and cons of antioxidants. Executive summary report. J Nutr 134(11):3143S\u20133163S. https:\/\/doi.org\/10.1093\/jn\/134.11.3143S","journal-title":"J Nutr"},{"issue":"9","key":"15_CR11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ETH (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938\u2013945. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1167","journal-title":"J Am Coll Cardiol"},{"issue":"S5","key":"15_CR12","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.21037\/tcr.2018.04.24","volume":"7","author":"D Cappetta","year":"2018","unstructured":"Cappetta D, Urbanek K, Rossi F, De Angelis A (2018) Anthracycline cardiotoxicity: new actors on the stage. Transl Cancer Res 7(S5):S580\u2013S583. https:\/\/doi.org\/10.21037\/tcr.2018.04.24","journal-title":"Transl Cancer Res"},{"issue":"February","key":"15_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-319-43096-6_2","volume":"5","author":"R Said","year":"2017","unstructured":"Said R, Nickolich M, Lenihan DJ, Tsimberidou AM (2017) Cardiotoxicity of anticancer therapies. Cardio-Oncology: Clin Overlap Cancer Heart Dis 5(February):15\u201342. https:\/\/doi.org\/10.1007\/978-3-319-43096-6_2","journal-title":"Cardio-Oncology: Clin Overlap Cancer Heart Dis"},{"issue":"2","key":"15_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11897-012-0083-y","volume":"9","author":"AY Shaikh","year":"2012","unstructured":"Shaikh AY, Shih JA (2012) Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep 9(2):117\u2013127. https:\/\/doi.org\/10.1007\/s11897-012-0083-y","journal-title":"Curr Heart Fail Rep"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.58","volume":"3","author":"MW Bloom","year":"2017","unstructured":"Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP et al (2017) Heart failure with reduced ejection fraction. Nat Rev Dis Primers 3:1\u201320. https:\/\/doi.org\/10.1038\/nrdp.2017.58","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"15_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12410-012-9163-3","volume":"5","author":"TC Tan","year":"2012","unstructured":"Tan TC, Scherrer-Crosbie M (2012) Assessing the cardiac toxicity of chemotherapeutic agents: role of echocardiography. Curr Cardiovasc Imaging Rep 5(6):403\u2013409. https:\/\/doi.org\/10.1007\/s12410-012-9163-3","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"15_CR17","doi-asserted-by":"publisher","unstructured":"Tan LL, Lyon AR (2018) Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med 20(7). https:\/\/doi.org\/10.1007\/s11936-018-0641-z","DOI":"10.1007\/s11936-018-0641-z"},{"key":"15_CR18","doi-asserted-by":"crossref","unstructured":"Nicol M, Baudet M, Cohen-solal A (2019) Co-morbidities subclinical left ventricular dysfunction during chemotherapy co-morbidities. Cardiac Failure Review 942:31\u201336","DOI":"10.15420\/cfr.2018.25.1"},{"key":"15_CR19","doi-asserted-by":"publisher","unstructured":"Moazeni S, Cadeiras M, Yang EH, Deng MC, Nguyen K-L (2017) Anthracycline induced cardiotoxicity: biomarkers and \u201cOmics\u201d technology in the era of patient specific care. Clin Transl Med 6(1). https:\/\/doi.org\/10.1186\/s40169-017-0148-3","DOI":"10.1186\/s40169-017-0148-3"},{"key":"15_CR20","unstructured":"Santos DS, Goldenberg RCS (2018) Doxorubicin-induced cardiotoxicity: from mechanisms to development of efficient therapy (Chapter 1). Cardiotoxicity: Intech Open, pp 3\u201324"},{"issue":"October 2017","key":"15_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, Abilash VG, Tirupathi Pichiah PB, Arunachalam S (2018) Molecular mechanism of doxorubicin-induced cardiomyopathy\u00a0\u2013 an update. Eur J Pharmacol 818(October 2017):241\u2013253. https:\/\/doi.org\/10.1016\/j.ejphar.2017.10.043","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"15_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2012","unstructured":"Volkova M, Russell R (2012) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7(4):214\u2013220. https:\/\/doi.org\/10.2174\/157340311799960645","journal-title":"Curr Cardiol Rev"},{"issue":"2","key":"15_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV et al (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig 124(2):617\u2013630. https:\/\/doi.org\/10.1172\/JCI72931","journal-title":"J Clin Investig"},{"issue":"23","key":"15_CR24","first-page":"8422","volume":"61","author":"G Minotti","year":"2001","unstructured":"Minotti G, Salvatorelli E, Menna P, Ronchi R, Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61(23):8422\u20138428","journal-title":"Cancer Res"},{"issue":"NOV","key":"15_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.01262","volume":"9","author":"CG Nebigil","year":"2018","unstructured":"Nebigil CG, D\u00e9saubry L (2018) Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol 9(NOV):1\u201313. https:\/\/doi.org\/10.3389\/fphar.2018.01262","journal-title":"Front Pharmacol"},{"issue":"6","key":"15_CR26","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52(6):1213\u20131225. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.03.006","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"15_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.11648\/j.ijcocr.20170202.12","volume":"2","author":"HM Alkuraishy","year":"2017","unstructured":"Alkuraishy HM, Al-gareeb AI, Al-hussaniy HA (2017) Doxorubicin-induced cardiotoxicity: molecular mechanism and protection by conventional drugs and natural products. Int J Clin Oncol Cancer Res 2(2):31\u201344. https:\/\/doi.org\/10.11648\/j.ijcocr.20170202.12","journal-title":"Int J Clin Oncol Cancer Res"},{"issue":"5","key":"15_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1021\/tx000013q","volume":"13","author":"S Licata","year":"2000","unstructured":"Licata S, Saponiero A, Mordente A, Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13(5):414\u2013420. https:\/\/doi.org\/10.1021\/tx000013q","journal-title":"Chem Res Toxicol"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcha.2015.11.004","volume":"10","author":"MA Mitry","year":"2016","unstructured":"Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasc 10:17\u201324. https:\/\/doi.org\/10.1016\/j.ijcha.2015.11.004","journal-title":"IJC Heart Vasc"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","volume":"293","author":"M Pecoraro","year":"2016","unstructured":"Pecoraro M, Del Pizzo M, Marzocco S, Sorrentino R, Ciccarelli M, Iaccarino G et al (2016) Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 293:44\u201352. https:\/\/doi.org\/10.1016\/j.taap.2016.01.006","journal-title":"Toxicol Appl Pharmacol"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CMAR.S47238","volume":"6","author":"SW Langer","year":"2014","unstructured":"Langer SW (2014) Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res 6:357\u2013363. https:\/\/doi.org\/10.2147\/CMAR.S47238","journal-title":"Cancer Manag Res"},{"issue":"1","key":"15_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0036-7","volume":"5","author":"S Ganatra","year":"2019","unstructured":"Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D et al (2019) Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology 5(1):1\u201312. https:\/\/doi.org\/10.1186\/s40959-019-0036-7","journal-title":"Cardio-Oncology"},{"issue":"3","key":"15_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/MPH.0000000000001112","volume":"40","author":"F Wang","year":"2018","unstructured":"Wang F, Iskra B, Kleinerman E, Alvarez-florez C, Andrews T, Shaw A et al (2018) Aerobic exercise during early murine doxorubicin exposure mitigates cardiac toxicity. J Pediatr Hematol Oncol 40(3):208\u2013215","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Advances in Experimental Medicine and Biology","Current Advances in Osteosarcoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-43032-0_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T15:17:47Z","timestamp":1722957467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-43032-0_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030430313","9783030430320"],"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-43032-0_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"2 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}